Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial
Stephen Kanes(Sage Therapeutics (United States)), Samantha Meltzer‐Brody(University of North Carolina at Chapel Hill), Shane Raines, Robert Riesenberg, Amy Schacterle(Sage Therapeutics (United States)), C. Neill Epperson(University of Pennsylvania), Kristina M. Deligiannidis(Zucker Hillside Hospital), Helen Colquhoun(Sage Therapeutics (United States)), Steven M. Paul(MIND Research Institute), Handan Gunduz‐Bruce(Sage Therapeutics (United States)), Jeffrey M. Jonas(Sage Therapeutics (United States)), James Doherty(Sage Therapeutics (United States)), David R. Rubinow(University of North Carolina at Chapel Hill), Ethan Hoffmann(Sage Therapeutics (United States)), Ryan Arnold(Sage Therapeutics (United States))
Cited by 474
Related Papers
Effects of Gonadal Steroids in Women With a History of Postpartum Depression
|American Journal of Psychiatry|2000|942
Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials
|The Lancet|2018|780
Differential Behavioral Effects of Gonadal Steroids in Women with and in Those without Premenstrual Syndrome
|New England Journal of Medicine|1998|766
Postmenopausal Hormone Therapy: An Endocrine Society Scientific Statement
|The Journal of Clinical Endocrinology & Metabolism|2010|678
The epidemiology of DSM-III-R bipolar I disorder in a general population survey
|Psychological Medicine|1997|605